Vivtex

Vivtex's Chief Scientific Officer, Thomas von Erlach, discussed advancements pushing boundaries in oral biologics delivery at the 2023 PODD: Partnership Opportunities in Drug Delivery Conference. Listen to the discussion on the full podcast, Micromachines, Biologic Approaches and New Tools Pushing the Boundaries in Oral Delivery, here: https://lnkd.in/dPWeSJgP

Vivtex's Chief Executive Officer, Maureen Deehan, will be presenting Vivtex's achievements in oral biologics delivery at the 2024 MIT Health Science Forum on Thursday September 26th, in Cambridge, MA. Experts will gather at the forum to share insights on the adoption of cutting-edge tools to derisk and accelerate the drug development process. View the full details about the forum and register at https://lnkd.in/eNF4YgcX

I am looking forward to productive discussions at BIO-Europe, November 4–6, 2024, in Stockholm, Sweden. Register here: https://lnkd.in/e3BPXDeF Informa Connect

Vivtex's Chief Executive Officer, Maureen Deehan, will be attending the Fierce Biotech Summit in Boston, MA from September 30th to October 1st. Connect with Maureen at the summit and gain valuable insights from industry leaders by registering at https://lnkd.in/gtM6CwrF

Vivtex is delighted to enter a strategic collaboration with Orbis Medicines, a leader in oral macrocycle drug discovery, to evaluate the oral bioavailability of Orbis’ portfolio of next-generation macrocycle drugs, ‘nCycles’, through the use of Vivtex’s GI-ORIS™ platform. Read more about this exciting collaboration in the oral macrocycle field: https://lnkd.in/eWXMVJCy.

Vivtex's Chief Scientific Officer, Thomas von Erlach, will be presenting Vivtex's most recent research on oral macromolecule delivery systems at The 14th American Drug Delivery & Formulation in San Diego, CA. Join the discussion on September 16 - 17 by registering at https://lnkd.in/gBsdY8FB.

We are pleased to announce that Vivtex has entered into a research and licensing agreement with Equillium, Inc., a clinical-stage biotechnology company developing novel therapeutics to treat severe autoimmune and inflammatory disorders. Vivtex and Equillium will collaborate to develop GI-targeted formulations for EQ302, Equillium’s first-in-class oral, bi-specific peptide therapy. Read more about the collaboration on our website, https://lnkd.in/e6Ns3Hyc!

Vivtex's Chief Scientific Officer, Thomas von Erlach, will be presenting at the Boulder Peptide Symposium 2024 on September 19th in Boulder, Colorado, the only conference focused solely on peptide therapeutics. In his presentation, he will discuss the most recent advancement at Vivtex to delivery peptide therapeutics orally using a high throughput formulation screening approach. Join this discussion by registering at https://lnkd.in/gXcki_cA.

Vivtex's Chief Scientific Officer, Thomas von Erlach, will be presenting at the Boulder Peptide Symposium 2024 on September 19th in Boulder, Colorado, the only conference focused solely on peptide therapeutics. In his presentation, he will discuss the most recent advancement at Vivtex to delivery peptide therapeutics orally using a high throughput formulation screening approach. Join this discussion by registering at https://lnkd.in/gXcki_cA.

We're excited to introduce Vivtex's new scientific advisors, Tomi Sawyer, Peptide Therapeutics Expert, and Ivor Elrifi, Intellectual Property and Transactions Advisor. Tomi is the Chief Drug Hunter & President of Maestro Therapeutics, a consulting/advisory enterprise supporting peptide drug discovery, which he founded in 2019. Ivor is the Chief Executive Officer of a publicly traded biotech company, and former global chair of Cooley LLP’s patent counseling and prosecution practice. Read more about Tomi and Ivor on our page: https://lnkd.in/e7Cm2TRw